Drug intelligence / Profile preview

DWC202004

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202004 is a code name for an investigational drug that has been used as a reference drug in clinical studies evaluating pharmacokinetics and safety in healthy adult volunteers. It was compared alongside other test drugs (DWJ1439, DWJ1464, DWC202003) in a randomized, open-label, oral, single-dose crossover study. The specific mechanism of action, therapeutic class, or primary indication for DWC202004 has not been disclosed publicly. The study sponsor and likely developer is Daewoong Pharmaceutical.

Beyond the preview

Go deeper on DWC202004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202004.

Explore the full profile